We claim:

1. A compound of Formula (I),



(I)

a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug, wherein:

A is

(a)  ; (b)  ; (c)  ;

(d)  ; (e)  ; (f)  ;

(g)  ; or, (h)  ;

P, including the carbon atoms to which it is attached, is (C_3-C_8)cycloalkyl, (C_3-C_8)heterocycloalkyl, aryl, or heteroaryl; optionally and independently substituted with from 1 to 3 substituents independently selected from halogen, (C_1-C_5)alkyl, (C_1-C_5)alkoxy, and trifluoromethyl;

J is O, S, -N(R^{15})-, -N(R^{15})CO-, -CON(R^{15})-, -SO_2 N(R^{15})-, or -N(R^{15}) SO_2-;

x is 0, 1, 2, 3, 4, 5, or 6;

R^{10} is -CO_2H, -CON$R^{30}R^{31}$, -$NR^{30}R^{31}$, or -N(R^{15})SO_2R^{40};

R^1 and R^2 are independently H or (C_1-C_3)alkyl;

R^3 is (C_1-C_8)alkyl, (C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkyl-methyl, (C_3-C_8)heterocycloalkyl, (C_3-C_8)heterocycloalkyl-methyl, aryl, or heteroaryl; optionally and

independently substituted with from 1 to 3 substituents independently selected from halogen, hydroxy, oxo, $(C_1$-$C_5)$alkyl, and $(C_1$-$C_5)$alkoxy;

R^{15} is H or $(C_1$-$C_5)$alkyl;

R^{30} and R^{31} are taken separately and are independently H, $(C_1$-$C_5)$alkyl, $(C_3$-$C_8)$cycloalkyl, $(C_3$-$C_8)$heterocycloalkyl, aryl, or heteroaryl, wherein said R^{30} and R^{31} are optionally and independently substituted with from 1 to 3 substituents independently selected from halogen, oxo, $(C_1$-$C_5)$alkyl, $-CO_2R^{40}$, $-COR^{40}$, $-OR^{40}$, $-CONR^{50}R^{51}$, $-NR^{50}R^{51}$, and $-SO_2R^{40}$; or

R^{30} and R^{31} are taken together with the nitrogen atom to which they are attached to form a 5- to 8-membered heterocycloalkyl ring, said ring optionally having 1 additional heteroatom independently selected from N, O, and S, wherein said 5- to 8- membered heterocycloalkyl ring is optionally and independently substituted with from 1 to 3 substituents independently selected from halogen, oxo, $(C_1$-$C_5)$alkyl, $-CO_2R^{40}$, $-COR^{40}$, $-OR^{40}$, $-CONR^{50}R^{51}$, $-NR^{50}R^{51}$, and $-SO_2R^{40}$;

R^{40} is H, $(C_1$-$C_5)$alkyl, $(C_3$-$C_8)$cycloalkyl, $(C_3$-$C_8)$heterocycloalkyl, aryl, heteroaryl;

R^{50} and R^{51} are taken separately and are independently H, $(C_1$-$C_5)$alkyl, $(C_3$-$C_8)$cycloalkyl, $(C_3$-$C_8)$heterocycloalkyl, aryl, or heteroaryl; or

R^{50} and R^{51} are taken together with the nitrogen atom to which they are attached to form a 5- to 8-membered heterocycloalkyl ring, said ring optionally having 1 additional heteroatom independently selected from N, O, and S.

2. A compound of claim 1 wherein:

A is (a), (b), (c), or (h).

R^1 and R^2 are H;

R^3 is $(C_3$-$C_6)$ alkyl or $(C_3$-$C_5)$ cycloalkyl;

P is $(C_3$-$C_8)$cycloalkyl or aryl;

J is O or S; and,

x is 1, 2, or 3.

3. A compound of claim 2 wherein:

A is (a) or (b).

4. A compound of claim 1 which is:

1-{[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetyl}-pyrrolidine-2-carboxylic acid;

1-{[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-acetyl}-pyrrolidine-2(S)-carboxylic acid

3-isopropyl-5-[2-(2-oxo-2-piperazin-1-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

1-cyclopentyl-6-[2-(2-oxo-2-piperazin-1-yl-ethoxy)-benzyl]-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one

3-isopropyl-5-[2-(2-morpholin-4-yl-2-oxo-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-isopropyl-5-[2-(2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

5-{2-[2-(4-ethyl-piperazin-1-yl)-2-oxo-ethoxy]-benzyl}-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

N,N-diethyl-2-[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetamide;

1-{[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetyl}-pyrrolidine-2-carboxylic acid methyl ester;

4-{[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetyl}-piperazine-1-carboxylic acid tert-butyl ester;

N-(2-dimethylamino-ethyl)-2-[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetamide;

1-{[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-acetyl}-pyrrolidine-2-carboxylic acid methyl ester;

4-{[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-acetyl}-piperazine-1-carboxylic acid tert-butyl ester;

1-cyclopentyl-6-[2-(2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one;

1-cyclopentyl-6-[2-(2-morpholin-4-yl-2-oxo-ethoxy)-benzyl]-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one;

2-[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-N-(2-dimethylamino-ethyl)-acetamide;

1-cyclopentyl-6-{2-[2-(4-ethyl-piperazin-1-yl)-2-oxo-ethoxy]-benzyl}-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one;

2-[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-N,N-diethyl-acetamide;

[2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-phenoxy]-acetic acid;

[2-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl)-phenoxy]-acetic acid;

3-isopropyl-5-[2-(5-chloro-2-morpholin-4-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d] pyrimidin-7-one;

3-isopropyl-5-[2-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-isopropyl-5-[2-(2-morpholin-4-yl-ethoxy)-cyclohexylmethyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

5-[5-fluoro-2-(2-morpholin-4-yl-ethoxy)-benzyl]-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-cyclopentyl-5-[5-fluoro-2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-isopropyl-5-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d] pyrimidin-7-one; .

9-(1,2-dimethyl-propyl)-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-9-(tetrahydro-furan-3-yl)-1,9-dihydro-purin-6-one;

5-[2-(2-diethylamino-ethoxy)-benzyl]-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-cyclopentyl-5-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

3-cyclobutyl-5-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

9-(1(R),2-dimethyl propyl)-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

9-(2-methyl-butyl)-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

9-cyclopentyl-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

5-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-3-pyridin-3-yl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one;

9-(1,2-dimethyl-propyl)-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

9-isopropyl-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-9-(tetrahydro-furan-2-ylmethyl)-1,9-dihydro-purin-6-one;

9-(1-isopropyl-2-methyl-propyl)-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

9-(1-ethyl-propyl)-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

9-cyclopentyl-8-methyl-2-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,9-dihydro-purin-6-one;

3-cyclopentyl-5-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-3,6-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one;

1-cyclopentyl-6-[2-(2-morpholin-4-yl-ethoxy)-benzyl]-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one;

9-cyclopentyl-2-[2-(3-morpholin-4-yl-propoxy)-benzyl]-1,9-dihydro-purin-6-one;

N-[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-yl]-2-pyrrolidin-1-yl-acetamide;

N-[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-yl]-2-morpholin-4-yl-acetamide;

2-diethylamino-N-[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-yl]-acetamide;

1-{[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-ylcarbamoyl]-methyl}-pyrrolidine-2(S)-carboxylic acid methyl ester;

2-cyclobutylamino-N-[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-yl]-acetamide; or

2-cyclopropylamino-N-[(1R,2S)2-(3-isopropyl-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethyl)-cyclohex-1-yl]-acetamide;

a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug.

5. A pharmaceutical composition comprising a compound of claim 1, a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug; and a pharmaceutically acceptable carrier, vehicle, or diluent.

6. A method of treating a condition, disease, or symptom selected from the group consisting of type 1 diabetes, type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and cardiovascular disease, wherein said method comprises administering to a mammal in need of such treatment or

prevention, a therapeutically effective amount of a compound of claim 1, a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug; or a pharmaceutical composition comprising said compound of claim 1, or said stereoisomer or prodrug thereof, or said pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug.

7. A method of claim 6 wherein said condition, disease, or symptom is diabetes or cardiovascular disease.

8. A method of inhibiting phosphodiesterase 9 activity in a mammal in need of such inhibition which method comprises administering a phosphodiesterase 9 inhibiting amount of a compound of claim 1, a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug; or a pharmaceutical composition comprising a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or prodrug, and a pharmaceutically acceptable carrier, vehicle, or diluent.